{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:15Z","timestamp":1788865995474,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["517063424"],"award-info":[{"award-number":["517063424"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024149","name":"UCB Pharma Germany","doi-asserted-by":"publisher","award":["ERoLO2020"],"award-info":[{"award-number":["ERoLO2020"]}],"id":[{"id":"10.13039\/100024149","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00198-026-07932-8","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:57:24Z","timestamp":1773280644000},"page":"1267-1278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-6794","authenticated-orcid":false,"given":"Felix N.","family":"von Brackel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Kornak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Barvencik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-5013","authenticated-orcid":false,"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"7","key":"7932_CR1","doi-asserted-by":"publisher","first-page":"e3048","DOI":"10.1210\/clinem\/dgac147","volume":"107","author":"R Oheim","year":"2022","unstructured":"Oheim R, Tsourdi E, Seefried L, Beller G, Schubach M, Vettorazzi E, St\u00fcrznickel J, Rolvien T, Ehmke N, Delsmann A, Genest F, Kr\u00fcger U, Zemojtel T, Barvencik F, Schinke T, Jakob F, Hofbauer LC, Mundlos S, Kornak U (2022) Genetic diagnostics in routine osteological assessment of adult low bone mass disorders. J Clin Endocrinol Metab 107(7):e3048\u2013e3057","journal-title":"J Clin Endocrinol Metab"},{"issue":"29","key":"7932_CR2","doi-asserted-by":"publisher","first-page":"26770","DOI":"10.1074\/jbc.M504308200","volume":"280","author":"M Sem\u00ebnov","year":"2005","unstructured":"Sem\u00ebnov M, Tamai K, He X (2005) SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280(29):26770\u201326775","journal-title":"J Biol Chem"},{"issue":"23","key":"7932_CR3","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22(23):6267\u20136276","journal-title":"EMBO J"},{"issue":"9","key":"7932_CR4","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1074\/jbc.M705092200","volume":"283","author":"AG Robling","year":"2008","unstructured":"Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. J Biol Chem 283(9):5866\u20135875","journal-title":"J Biol Chem"},{"issue":"2","key":"7932_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jbmr.4197","volume":"36","author":"J St\u00fcrznickel","year":"2021","unstructured":"St\u00fcrznickel J, Rolvien T, Delsmann A, Butscheidt S, Barvencik F, Mundlos S, Schinke T, Kornak U, Amling M, Oheim R (2021) Clinical phenotype and relevance of LRP5 and LRP6 variants in patients with early-onset osteoporosis (EOOP). J Bone Miner Res 36(2):271\u2013282","journal-title":"J Bone Miner Res"},{"key":"7932_CR6","doi-asserted-by":"crossref","unstructured":"Luther J, Yorgan TA, Rolvien T, Ulsamer L, Koehne T, Liao N, Keller D, Vollersen N, Teufel S, Neven M, Peters S, Schweizer M, Trumpp A, Rosigkeit S, Bockamp E, Mundlos S, Kornak U, Oheim R, Amling M, Schinke T, David J-P. Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand. Sci Transl Med. 2018 Nov 7;10(466):eaau7137.","DOI":"10.1126\/scitranslmed.aau7137"},{"issue":"1","key":"7932_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jbm4.10020","volume":"2","author":"C Collet","year":"2018","unstructured":"Collet C, Ostertag A, Ricquebourg M, Delecourt M, Tueur G, Isidor B, Guillot P, Schaefer E, Javier R-M, Funck-Brentano T, Orcel P, Laplanche J-L, Cohen-Solal M (2018) Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes. JBMR Plus 2(1):12\u201321","journal-title":"JBMR Plus"},{"issue":"6","key":"7932_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10741","volume":"7","author":"S Fabre","year":"2023","unstructured":"Fabre S, Bourmaud M, Mabilleau G, Goulet R, Couturier A, Dentel A, Picaud S, Funck-Brentano T, Collet C, Cohen-Solal M (2023) Lrp5 p.Val667Met variant compromises bone mineral density and matrix properties in osteoporosis. JBMR Plus 7(6):e10741","journal-title":"JBMR Plus"},{"key":"7932_CR9","doi-asserted-by":"crossref","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. New England Journal of Medicine. Massachusetts Medical Society; 2017 Oct 12;377(15):1417\u201327.","DOI":"10.1056\/NEJMoa1708322"},{"key":"7932_CR10","doi-asserted-by":"crossref","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine. Massachusetts Medical Society; 2016 Oct 20;375(16):1532\u201343.","DOI":"10.1056\/NEJMoa1607948"},{"issue":"1","key":"7932_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae238","volume":"3","author":"EFS van Velsen","year":"2025","unstructured":"van Velsen EFS, Wijnen M, Muradin GSR, Zillikens MC (2025) Incident vertebral fractures during romosozumab treatment in a patient with a pathogenic LRP5 variant. JCEM Case Rep 3(1):luae238","journal-title":"JCEM Case Rep"},{"key":"7932_CR12","doi-asserted-by":"crossref","unstructured":"Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med. 2013 Nov 13;5(211):211ra158.","DOI":"10.1126\/scitranslmed.3006627"},{"key":"7932_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115708","volume":"143","author":"K-E Lim","year":"2021","unstructured":"Lim K-E, Bullock WA, Horan DJ, Williams BO, Warman ML, Robling AG (2021) Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration. Bone 143:115708","journal-title":"Bone"},{"issue":"12","key":"7932_CR14","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/ajmg.a.37365","volume":"167A","author":"L Bonafe","year":"2015","unstructured":"Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S, Nishimura G, Sangiorgi L, Savarirayan R, Sillence D, Spranger J, Superti-Furga A, Warman M, Unger S (2015) Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 167A(12):2869\u20132892","journal-title":"Am J Med Genet A"},{"issue":"5","key":"7932_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u201324","journal-title":"Genet Med"},{"issue":"3","key":"7932_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.101036","volume":"26","author":"RJ Schmidt","year":"2024","unstructured":"Schmidt RJ, Steeves M, Bayrak-Toydemir P, Benson KA, Coe BP, Conlin LK, Ganapathi M, Garcia J, Gollob MH, Jobanputra V, Luo M, Ma D, Maston G, McGoldrick K, Palculict TB, Pesaran T, Pollin TI, Qian E, Rehm HL, Riggs ER, Schilit SLP, Sergouniotis PI, Tvrdik T, Watkins N, Zec L, Zhang W, Lebo MS, ClinGen Low Penetrance\/Risk Allele Working Group (2024) Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance\/Risk Allele Working Group. Genet Med 26(3):101036","journal-title":"Genet Med"},{"key":"7932_CR17","doi-asserted-by":"crossref","unstructured":"Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA. Executive summary of the 2019 ISCD Position Development Conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. Journal of Clinical Densitometry. 2019 Oct 1;22(4):453\u201371.","DOI":"10.1016\/j.jocd.2019.07.001"},{"key":"7932_CR18","doi-asserted-by":"crossref","unstructured":"Whittier DE, Boyd SK, Burghardt AJ, Paccou J, Ghasem-Zadeh A, Chapurlat R, Engelke K, Bouxsein ML. Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography. Osteoporos Int. 2020 Sept 1;31(9):1607\u201327.","DOI":"10.1007\/s00198-020-05438-5"},{"issue":"6","key":"7932_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00223-023-01143-7","volume":"113","author":"M Bartosik","year":"2023","unstructured":"Bartosik M, Simon A, Strahl A, Oheim R, Amling M, Schmidt FN (2023) Comparison of motion grading in 1,000 patients by first- and second-generation HR-pQCT: a propensity score matched cohort study. Calcif Tissue Int 113(6):597\u2013608","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"7932_CR20","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/jbmr.3128","volume":"32","author":"SL Manske","year":"2017","unstructured":"Manske SL, Davison EM, Burt LA, Raymond DA, Boyd SK (2017) The estimation of second-generation HR-pQCT from first-generation HR-pQCT using in vivo cross-calibration. J Bone Miner Res 32(7):1514\u20131524","journal-title":"J Bone Miner Res"},{"issue":"4","key":"7932_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jocd.2010.06.002","volume":"13","author":"K Hind","year":"2010","unstructured":"Hind K, Oldroyd B, Truscott JG (2010) In vivo precision of the GE Lunar iDXA densitometer for the measurement of total-body, lumbar spine, and femoral bone mineral density in adults. J Clin Densitom 13(4):413\u2013417","journal-title":"J Clin Densitom"},{"issue":"2","key":"7932_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-022-06523-7","volume":"34","author":"F Marini","year":"2023","unstructured":"Marini F, Giusti F, Palmini G, Brandi ML (2023) Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders. Osteoporos Int 34(2):213\u2013238","journal-title":"Osteoporos Int"},{"issue":"8","key":"7932_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10779","volume":"7","author":"J St\u00fcrznickel","year":"2023","unstructured":"St\u00fcrznickel J, Butscheidt S, Amling M, Oheim R (2023) Dynamics of skeletal status under optimized management during subsequent pregnancy in three women with a history of pregnancy- and lactation-associated osteoporosis carrying pathogenic variants in WNT1 and LRP5. JBMR Plus 7(8):e10779","journal-title":"JBMR Plus"},{"key":"7932_CR24","doi-asserted-by":"crossref","unstructured":"Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ. 1994 Sept 17;309(6956):691\u20135.","DOI":"10.1136\/bmj.309.6956.691"},{"issue":"9","key":"7932_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/oxfordjournals.aje.a009541","volume":"147","author":"H Burger","year":"1998","unstructured":"Burger H, de Laet CEDH, van Daele PLA, Weel AEAM, Witteman JCM, Hofman A, Pols HAP (1998) Risk factors for increased bone loss in an elderly population the Rotterdam Study. Am J Epidemiol 147(9):871\u20139","journal-title":"Am J Epidemiol"},{"issue":"1","key":"7932_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","volume":"1","author":"MR McClung","year":"2018","unstructured":"McClung MR (2018) Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia 1(1):11\u20135","journal-title":"Osteoporos Sarcopenia"},{"key":"7932_CR27","doi-asserted-by":"crossref","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. New England Journal of Medicine. Massachusetts Medical Society; 2014 Jan 30;370(5):412\u201320.","DOI":"10.1056\/NEJMoa1305224"},{"key":"7932_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215","journal-title":"Bone"},{"key":"7932_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574","journal-title":"Bone"},{"issue":"12","key":"7932_CR30","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1002\/jbmr.157","volume":"25","author":"AJ Burghardt","year":"2010","unstructured":"Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S (2010) A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res 25(12):2558\u201371","journal-title":"J Bone Miner Res"},{"issue":"10","key":"7932_CR31","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s00198-013-2349-y","volume":"24","author":"AL Schafer","year":"2013","unstructured":"Schafer AL, Burghardt AJ, Sellmeyer DE, Palermo L, Shoback DM, Majumdar S, Black DM (2013) Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS). Osteoporos Int 24(10):2591\u20132601","journal-title":"Osteoporos Int"},{"issue":"10","key":"7932_CR32","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1210\/jc.2011-3361","volume":"97","author":"M-SM Ardawi","year":"2012","unstructured":"Ardawi M-SM, Rouzi AA, Qari MH (2012) Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab 97(10):3691\u20133699","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7932_CR33","first-page":"535","volume":"102","author":"V-V V\u00e4lim\u00e4ki","year":"2017","unstructured":"V\u00e4lim\u00e4ki V-V, M\u00e4kitie O, Pereira R, Laine C, Wesseling-Perry K, M\u00e4\u00e4tt\u00e4 J, Kirjavainen M, Viljakainen H, V\u00e4lim\u00e4ki MJ (2017Feb 1) Teriparatide treatment in patients with WNT1 or PLS3 mutation-related early-onset osteoporosis: a pilot study. J Clin Endocrinol Metab 102(2):535\u2013544","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"7932_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S, Studer U, Steiner C, Ziswiler H-R, Sromek K, Schmid G, Gahl B, H\u00e4uselmann H, Reichenbach S, Lehmann T (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35(9):1605\u20131613","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07932-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:55Z","timestamp":1788865435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07932-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7932"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07932-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FvB, ND, UK, TS, MA have no conflict of interest. FB has received speaker fees from Alexion, UCB, and Diasorin and has received institutional research grants from UCB and Alexion. RO has served as a speaker and advisory board member for Kyowa Kirin, Inozyme, Ipsen, Pharmacosmos, UCB, and Mereo and has received an institutional research grant from Kyowa Kirin, UCB, and Inozyme.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}